Regulus reducing headcount by 30%

Regulus Therapeutics Inc. (NASDAQ:RGLS) said it reduced headcount across the company by about 30% to 65. At Dec. 31, 2016, the company had 97 employees. Regulus said the restructuring will lead to annual savings of $6 million.

President and CEO Paul Grint resigned. The company promoted COO Joseph Hagan to succeed Grint. Regulus also promoted Daniel Chevallard to CFO from VP of finance and accounting...